These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 33995536)
1. Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia. Suwantika AA; Zakiyah N; Abdulah R; Sitohang V; Tandy G; Anartati A; Hidayatullah T; Herliana P; Hadinegoro SR J Environ Public Health; 2021; 2021():7494965. PubMed ID: 33995536 [TBL] [Abstract][Full Text] [Related]
2. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines. Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay. Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155 [TBL] [Abstract][Full Text] [Related]
4. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944 [TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Wu DB; Roberts C; Lee VW; Hong LW; Tan KK; Mak V; Lee KK Hum Vaccin Immunother; 2016; 12(2):403-16. PubMed ID: 26451658 [TBL] [Abstract][Full Text] [Related]
6. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option. Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden. Klok RM; Lindkvist RM; Ekelund M; Farkouh RA; Strutton DR Clin Ther; 2013 Feb; 35(2):119-34. PubMed ID: 23312274 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Mezones-Holguin E; Canelo-Aybar C; Clark AD; Janusz CB; Jaúregui B; Escobedo-Palza S; Hernandez AV; Vega-Porras D; González M; Fiestas F; Toledo W; Michel F; Suárez VJ Vaccine; 2015 May; 33 Suppl 1():A154-66. PubMed ID: 25919156 [TBL] [Abstract][Full Text] [Related]
9. How cost effective is switching universal vaccination from PCV10 to PCV13? A case study from a developing country. Castañeda-Orjuela C; De la Hoz-Restrepo F Vaccine; 2018 Sep; 36(38):5766-5773. PubMed ID: 30087049 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163 [TBL] [Abstract][Full Text] [Related]
11. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children. Ayieko P; Griffiths UK; Ndiritu M; Moisi J; Mugoya IK; Kamau T; English M; Scott JA PLoS One; 2013; 8(6):e67324. PubMed ID: 23826268 [TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of 13-valent pneumococcal conjugate vaccination in Mongolia. Sundaram N; Chen C; Yoong J; Luvsan ME; Fox K; Sarankhuu A; La Vincente S; Jit M Vaccine; 2017 Feb; 35(7):1055-1063. PubMed ID: 28109706 [TBL] [Abstract][Full Text] [Related]
13. A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children. Vemer P; Postma MJ Hum Vaccin Immunother; 2014; 10(7):1841-9. PubMed ID: 25424791 [TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of pneumococcal conjugate vaccination in The Gambia. Kim SY; Lee G; Goldie SJ BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900 [TBL] [Abstract][Full Text] [Related]
15. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Kuhlmann A; von der Schulenburg JG Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada. Earnshaw SR; McDade CL; Zanotti G; Farkouh RA; Strutton D BMC Infect Dis; 2012 Apr; 12():101. PubMed ID: 22530841 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. Smith KJ; Wateska AR; Nowalk MP; Raymund M; Nuorti JP; Zimmerman RK JAMA; 2012 Feb; 307(8):804-12. PubMed ID: 22357831 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia. Suwantika AA; Supadmi W; Ali M; Abdulah R PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009664. PubMed ID: 34383764 [TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: protection at what price in the Thai context? Kulpeng W; Leelahavarong P; Rattanavipapong W; Sornsrivichai V; Baggett HC; Meeyai A; Punpanich W; Teerawattananon Y Vaccine; 2013 Jun; 31(26):2839-47. PubMed ID: 23588084 [TBL] [Abstract][Full Text] [Related]